In-depth insight into our company and the exciting business of the ever advancing world of medical isotope technology. The video features many of our current Management team as well as the inclusion of Dr. Barry Pressman, Chairman - Medical Advisory Board.
One of AMIC's future goals is to produce the medical imaging isotope Technetium-99m. This critical imaging isotope is created from another commonly known isotope Molybdenum-99 (Mo-99).
Nuclear Fission is used to produce the radioactive substance, Technetium-99m from Molydenum-99. Technetium-99m is employed in more than 16 million nuclear imaging procedures per-year in the US alone.
Vital procedures ranging from sentinel node biopsies in cancer surgery to bone scans and cardiac stress tests are threatened by current shortages of Mo-99. With aging production reactors closing or experiencing problems, the US must import 100% of it’s Mo-99. AMIC, with its partners, is developing a way to produce Mo-99 and other critical radioisotopes domestically using an efficient compact accelerator instead of a nuclear reactor. This concept will save a significant amount of money and time in production. AMIC is moving this project forward and will be announcing progress as developments are confirmed.
Medical diagnostic imaging techniques using Technetium-99m account for roughly 80% of all nuclear medicine procedures. This represents over 30 million examinations worldwide every year.
Disruptions in the supply chain of these medical isotopes – which have half-lives of 66 hours for molybedenum-99 (99Mo) and 6 hours for its daughter isotope, technetium-99m (99mTc), and thus must be produced continually – can lead to cancellations or delays in important medical testing services.
Unfortunately, supply and reliability has declined over the past decade due to unexpected or extended shutdowns at the few aging 99Mo producing research reactor and processing facilities. These shutdowns have created global supply shortages.
Although there is currently no commercial production of Mo-99 in the United States, this was not always the case. Prior to 1989, Cintichem, Inc. produced Mo-99 for the U.S. market using a 5 MWt (megawatt thermal) research reactor located in Tuxedo, New York. This reactor was shut down when tritium contamination of surface waters adjacent to the reactor site was confirmed. A decision to decommission the reactor was subsequently made after a risk-benefit study carried out by Cintichem’s parent company, Hoffman- LaRoche, determined that its continued operation was not justified. Cintichem offered to arrange a long-term supply agreement with the other North American supplier, the Canadian company Nordion (later MDS Nordion), to supply Mo-99 to U.S. technetium generator manufacturers (Amersham [now GE Healthcare], Mallinckrodt, and DuPont(*1).
(￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼￼*1) Of these three, only Mallinckrodt continues to supply technetium generators to the U.S. market.